MX2021010218A - Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo. - Google Patents

Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo.

Info

Publication number
MX2021010218A
MX2021010218A MX2021010218A MX2021010218A MX2021010218A MX 2021010218 A MX2021010218 A MX 2021010218A MX 2021010218 A MX2021010218 A MX 2021010218A MX 2021010218 A MX2021010218 A MX 2021010218A MX 2021010218 A MX2021010218 A MX 2021010218A
Authority
MX
Mexico
Prior art keywords
protein
preparation
wdr5
inhibitor
aniline
Prior art date
Application number
MX2021010218A
Other languages
English (en)
Inventor
Jun Xu
Xin Chen
Qidong You
Xiaoke Guo
Xiaoli Xu
Dongdong Li
Weilin Chen
Jing Gu
Zhengyu Jiang
Original Assignee
Univ China Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ China Pharma filed Critical Univ China Pharma
Publication of MX2021010218A publication Critical patent/MX2021010218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación describe un inhibidor de la interacción proteína-proteína WDR5, que incluye un compuesto que tiene una estructura representada por la fórmula general (I). Los experimentos muestran que el inhibidor actúa sobre una proteína WDR5 y una proteína de interacción de la misma que incluye, pero no se limita a, MLL, inhibe selectivamente la proliferación de células leucémicas e inhibe la metilación de H3K4 y la expresión del gen Hox / Meis-1 corriente abajo en el nivel celular. La presente divulgación también describe un método para preparar el inhibidor y el uso del mismo en la preparación de un fármaco para tratar la leucemia aguda y otras enfermedades relacionadas. (ver Fórmula).
MX2021010218A 2019-02-26 2019-03-22 Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo. MX2021010218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910139980.6A CN109734674B (zh) 2019-02-26 2019-02-26 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
PCT/CN2019/079160 WO2020172932A1 (zh) 2019-02-26 2019-03-22 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途

Publications (1)

Publication Number Publication Date
MX2021010218A true MX2021010218A (es) 2021-10-26

Family

ID=66368322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010218A MX2021010218A (es) 2019-02-26 2019-03-22 Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo.

Country Status (14)

Country Link
US (1) US20220152027A1 (es)
EP (1) EP3932910A4 (es)
JP (1) JP2022526219A (es)
KR (1) KR20210137064A (es)
CN (1) CN109734674B (es)
AU (1) AU2019431157A1 (es)
BR (1) BR112021016861A2 (es)
CA (1) CA3131285A1 (es)
CL (1) CL2021002234A1 (es)
CO (1) CO2021012375A2 (es)
IL (1) IL285852A (es)
MX (1) MX2021010218A (es)
SG (1) SG11202109305XA (es)
WO (1) WO2020172932A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023097422A1 (zh) * 2021-11-30 2023-06-08 首都医科大学附属北京口腔医院 Kdm6b的多肽序列及对间充质干细胞功能的调控应用
US20230293539A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
WO2024015478A2 (en) * 2022-07-14 2024-01-18 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN104844573A (zh) * 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
US10980807B2 (en) * 2016-02-09 2021-04-20 Inventisbio Llc Inhibitor of indoleamine-2,3-dioxygenase (IDO)
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂

Also Published As

Publication number Publication date
IL285852A (en) 2021-10-31
KR20210137064A (ko) 2021-11-17
CN109734674A (zh) 2019-05-10
BR112021016861A2 (pt) 2021-11-30
WO2020172932A1 (zh) 2020-09-03
AU2019431157A1 (en) 2021-10-14
CN109734674B (zh) 2022-08-26
CL2021002234A1 (es) 2022-05-27
JP2022526219A (ja) 2022-05-24
EP3932910A1 (en) 2022-01-05
CA3131285A1 (en) 2020-09-03
SG11202109305XA (en) 2021-09-29
US20220152027A1 (en) 2022-05-19
CO2021012375A2 (es) 2021-11-19
EP3932910A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
MX2021010218A (es) Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo.
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
MX2023001689A (es) Inhibidores de bcl-2.
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
MX2020007392A (es) Compuestos de benzamida.
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
EA201792116A1 (ru) Ингибитор янус-киназы
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
AR060150A1 (es) Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular
BR112021017049A2 (pt) Derivados de tiazol como inibidores de secreção de proteínas
EA201291073A1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
BR112018074238A2 (pt) combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b
MX2021012750A (es) Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
Bongiorno-Borbone et al. Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022010512A (es) Inhibidores de proteína bcl-2.
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
PH12017501369A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2022003270A (es) Compuesto de amida heterocíclica, sal farmacéuticamente aceptable delmismo y método de preparación y uso del mismo.
WO2016163799A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물
NZ745474A (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
MX2021009170A (es) Cristal de compuesto de diariltiohidantoina.